New heart valve implant could offer hope for moderate aortic stenosis patients
NCT ID NCT07532317
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares a new heart valve implant (Myval) to standard medication in 778 people aged 65+ with moderate aortic stenosis. The goal is to see if the implant reduces death, stroke, heart failure, and improves quality of life over 2 years. Participants will be randomly assigned to get the implant or continue medical therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Myval transcatheter heart valve (a device implanted via a catheter to replace the aortic valve)
- What this could lead to
- If successful, this could offer a less invasive treatment option for moderate aortic stenosis, potentially reducing the risk of death, stroke, and heart failure compared to medication alone.
- What could go wrong
- This is an early-stage trial (Phase NA) with no results yet. The device may not prove better than standard care, and there are risks like stroke, bleeding, or kidney injury from the procedure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE AORTIC STENOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.